Preventing Pruritus in Atopic Dermatitis: Are Biologics an Answer? WCM24 CME Satellite Symposium
Preventing Pruritus in Atopic Dermatitis: Are Biologics an Answer
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
At the completion of this activity, participants should be better able to:
Discuss the burden of itch on quality of life
Describe the pathophysiology of itch in atopic dermatitis
Analyze safety and efficacy data for current and emerging biologic therapies that target itch pathways in atopic dermatitis
Demonstrate strategies to individualize care to manage itch with biologic therapies in atopic dermatitis
Mona Shahriari, MD
Central CT Dermatology
Joshua Zeichner, MD
Director of Cosmetic and Clinical Research
Icahn School of Medicine at Mount Sinai
New York, NY
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
Consultant: Abbvie, Allergan, Arcutis, Beiersdorf, Dermavant, Galderma, Incyte, Kenvue, L'Oreal, Pfizer, Procter & Gamble, Sun, Unilever, UCB
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.